The economic profile of peginterferon beta-1a in the treatment of relapsing-remitting multiple sclerosis in Italy

Table 3 CEA of peginterferon beta-1a vs the other injectable first line DMTs in Italy from the societal perspective

Outcomes		peg-IFN β-1a 125 μg	IFN β-1a30 μg	IFN β-1a22 μg	IFN β-1a44 μg	IFN β-1b250 μg^a	IFN β-1b250 μg^b	GA 20 mg
Clinical outcomes
	LYs	19.94	19.71	19.73	19.81	19.68	19.68	19.68
	QALYs	9.07	8.09	8.19	8.55	8.06	8.06	8.15
[a]			0.98	0.87	0.51	1.01	1.01	0.92
Direct medical costs (€)
	Drugs & mon.	113,095	92,599	93,511	129,261	92,105	86,019	82,887
	Relapses	8789	9331	9078	8768	8808	8808	8502
	Adverse evts.	102	153	107	150	110	110	94
	Disease man.	111,107	120,152	119,651	116,368	121,277	121,277	121,424
Indirect and non-medical costs (€)
	Relapses	8901	9453	9196	8882	8922	8922	8613
	Other costs	528,222	586,700	583,313	561,586	594,367	594,357	595,374
Total cost		770,213	818,388	814,585	825,015	825,689	819,503	816,894
[b]			−48,175	−44,372	−54,801	−55,475	−49,289	−46,681
ICER (€) [c]			dominant	dominant	dominant	dominant	dominant	dominant

ISSN: 2056-6115